MD Biosciences has expanded its preclinical contract research services with a new suite of in vivo and in vitro cancer models. The company’s oncology research program specializes in murine solid tumors for subcutaneous and orthoptopic models (for example, advanced breast cancer and renal cancer) with a specific focus on the immune aspects of disease development and progression.   The services include both syngeneic and xenograft models with readouts for immune cell distribution, biomarkers, et...